CMBA
SGMO

C.M. Bidwell & Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

C.M. Bidwell & Associates’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,305
Closed -$40K – 598
2021
Q4 		$40K Buy
+5,305
New +$46.1K 0.02% 319
2021
Q2 		– Sell
-12,401
Closed -$155K – 616
2021
Q1 		$155K Buy
12,401
+1,651
+15% +$22.2K 0.11% 173
2020
Q4 		$168K Buy
10,750
+7,135
+197% +$83.6K 0.14% 144
2020
Q3 		$34K Buy
+3,615
New +$39.1K 0.03% 284

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

C.M. Bidwell & Associates's SGMO Position: Q1 2022 in Review

C.M. Bidwell & Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2022, closing a stake of 5,305 shares — an estimated $40K sold.

C.M. Bidwell & Associates first reported a position in SGMO in Q3 2020 and held it in 4 quarters. The position peaked at $168K in Q4 2020. 195 funds tracked by Wall St. Rank hold SGMO as of Q1 2022.

  • C.M. Bidwell & Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 5,305 SANGAMO THERAPEUTICS INC shares in Q1 2022, an estimated $40K.
  • C.M. Bidwell & Associates first reported a position in SANGAMO THERAPEUTICS INC in Q3 2020 and held it in 4 quarters.
  • C.M. Bidwell & Associates's SANGAMO THERAPEUTICS INC position peaked at $168K in Q4 2020.
  • 195 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.